Cellebrite DI Ltd. (NASDAQ:CLBT) Shares Purchased by Meitav Investment House Ltd.

Meitav Investment House Ltd. lifted its holdings in Cellebrite DI Ltd. (NASDAQ:CLBT) by 29.7% in the 3rd quarter, Holdings Channel.com reports. The fund owned 2,066,322 shares of the company’s stock after buying an additional 473,293 shares during the quarter. Meitav Investment House Ltd.’s holdings in Cellebrite DI were worth $34,797,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Pathway Financial Advisers LLC grew its holdings in Cellebrite DI by 1,583.8% during the 3rd quarter. Pathway Financial Advisers LLC now owns 4,378 shares of the company’s stock valued at $74,000 after purchasing an additional 4,118 shares in the last quarter. Tower View Wealth Management LLC grew its holdings in Cellebrite DI by 1.2% during the 3rd quarter. Tower View Wealth Management LLC now owns 130,647 shares of the company’s stock worth $2,200,000 after acquiring an additional 1,500 shares in the last quarter. Juncture Wealth Strategies LLC boosted its holdings in shares of Cellebrite DI by 42.2% in the 3rd quarter. Juncture Wealth Strategies LLC now owns 59,498 shares of the company’s stock valued at $1,002,000 after buying an additional 17,652 shares during the period. Strategic Advisors LLC acquired a new position in shares of Cellebrite DI in the 3rd quarter valued at about $474,000. Finally, Point72 Asia Singapore Pte. Ltd. boosted its holdings in shares of Cellebrite DI by 59.6% in the 2nd quarter. Point72 Asia Singapore Pte. Ltd. now owns 2,724 shares of the company’s stock valued at $33,000 after buying an additional 1,017 shares during the period. Institutional investors and hedge funds own 45.88% of the company’s stock.

Cellebrite DI Trading Up 0.1 %

CLBT stock opened at $18.37 on Thursday. Cellebrite DI Ltd. has a 52 week low of $6.55 and a 52 week high of $18.75. The company has a market capitalization of $3.78 billion, a price-to-earnings ratio of -34.64, a price-to-earnings-growth ratio of 2.52 and a beta of 1.52. The firm’s 50-day moving average is $17.38 and its two-hundred day moving average is $13.91.

Cellebrite DI (NASDAQ:CLBT) last released its quarterly earnings results on Thursday, August 15th. The company reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of $0.08 by $0.02. Cellebrite DI had a negative net margin of 28.51% and a positive return on equity of 5,902.06%. The company had revenue of $95.70 million for the quarter, compared to the consensus estimate of $91.94 million. During the same period in the previous year, the firm earned $0.05 EPS. Cellebrite DI’s revenue was up 24.8% on a year-over-year basis. On average, equities research analysts predict that Cellebrite DI Ltd. will post 0.31 earnings per share for the current year.

Analyst Ratings Changes

CLBT has been the subject of several research reports. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Cellebrite DI from $15.00 to $18.00 and gave the company a “buy” rating in a report on Friday, August 16th. TD Cowen boosted their target price on shares of Cellebrite DI from $20.00 to $23.00 and gave the company a “buy” rating in a research note on Monday, September 23rd. Needham & Company LLC boosted their target price on shares of Cellebrite DI from $14.00 to $17.00 and gave the company a “buy” rating in a research note on Friday, August 16th. Lake Street Capital boosted their target price on shares of Cellebrite DI from $13.50 to $17.00 and gave the company a “buy” rating in a research note on Friday, August 16th. Finally, Craig Hallum boosted their target price on shares of Cellebrite DI from $20.00 to $23.00 and gave the company a “buy” rating in a research note on Wednesday, September 25th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $18.57.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.